Other languages Cerus Corporation

Equities

CERS

US1570851014

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.72 ^USD	+2.99%		+3.61%	-20.37%

12/04	Craig-Hallum Starts Cerus With Buy Rating, $5 Price Target	MT
26/03	Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life	26/03
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients	19/03
Cerus Insider Sold Shares Worth $256,377, According to a Recent SEC Filing	15/03
Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024	06/03
Cerus Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024	08/01
Top Premarket Decliners	06/11
Cerus Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023	03/11
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on Its Digital Marketplace	02/11
Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer	27/23/27
Cerus Corporation Revises Revenue Guidance for the Year 2023	03/23/03
Cerus Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03
Cerus Gets $8.7 Million Additional Funding From US Department of Defense for Development of Lyophilized Cryoprecipitate	05/23/05
Cerus Corporation Announces Follow-On Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate	05/23/05
Cerus Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05
Cerus Corporation Reiterates Revenue Guidance for the Year 2023	05/23/05
Cerus' Q4 Loss Widens, Revenue Increases; Shares Drop After Hours	01/23/01
Cerus Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01
Cerus Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/23/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cerus Corporation

Equities

CERS

US1570851014

Other languages

Filters